BNP Paribas Financial Markets Invests $221,000 in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

BNP Paribas Financial Markets bought a new stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 20,885 shares of the company’s stock, valued at approximately $221,000.

Several other institutional investors have also recently added to or reduced their stakes in the stock. SkyOak Wealth LLC grew its stake in shares of Neumora Therapeutics by 33.3% in the fourth quarter. SkyOak Wealth LLC now owns 20,000 shares of the company’s stock worth $212,000 after acquiring an additional 5,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Neumora Therapeutics in the 4th quarter valued at about $61,000. Charles Schwab Investment Management Inc. increased its position in Neumora Therapeutics by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 704,154 shares of the company’s stock valued at $7,464,000 after acquiring an additional 5,899 shares during the period. PNC Financial Services Group Inc. acquired a new position in Neumora Therapeutics during the 4th quarter worth approximately $64,000. Finally, Quantbot Technologies LP acquired a new position in Neumora Therapeutics during the 4th quarter worth approximately $92,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Trading Up 2.3%

NMRA opened at $0.72 on Thursday. The business’s 50 day moving average is $0.76 and its 200-day moving average is $3.71. The stock has a market cap of $115.71 million, a PE ratio of -0.38 and a beta of 2.96. Neumora Therapeutics, Inc. has a twelve month low of $0.61 and a twelve month high of $17.19.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.02). As a group, analysts forecast that Neumora Therapeutics, Inc. will post -1.61 EPS for the current year.

Analyst Ratings Changes

NMRA has been the topic of several research analyst reports. Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. HC Wainwright dropped their price objective on Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. William Blair downgraded Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 10th. Bank of America restated an “underperform” rating and set a $1.00 target price (down from $7.00) on shares of Neumora Therapeutics in a research note on Wednesday, April 2nd. Finally, Guggenheim downgraded Neumora Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, March 7th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $9.29.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.